China Shineway Pharmaceutical (2877) Announces RMB 2,415 Million Turnover for First Nine Months of 2025

Bulletin Express

Nov 07

China Shineway Pharmaceutical Group Limited (2877) recorded a turnover of RMB 2,415 million for the nine months ended 30 September 2025, reflecting a 16.3% decrease compared with the same period in 2024. Major product categories all reported lower turnover: injection products amounted to RMB 786 million (down 23.6%), soft capsule products reached RMB 337 million (down 13.7%), granule products registered RMB 391 million (down 14.5%), TCM formula granule products totaled RMB 726 million (down 11.8%), and products in other forms stood at RMB 175 million (down 6.1%).

In terms of product mix, injection products accounted for approximately 32.5% of the total turnover during the period, followed by TCM formula granule products at 30.1%. Soft capsule and granule products accounted for around 14.0% and 16.2%, respectively, while products in other forms represented the remainder, reflecting the group’s diversified product portfolio.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/1142444254"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1142444254\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1142444254?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 12:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1142444254","market":"hk","top_or_hot":-1,"title":"China Shineway Pharmaceutical (2877) Announces RMB 2,415 Million Turnover for First Nine Months of 2025","media":"Bulletin Express","content":"<p>China Shineway Pharmaceutical Group Limited (2877) recorded a turnover of RMB 2,415 million for the nine months ended 30 September 2025, reflecting a 16.3% decrease compared with the same period in 2024. Major product categories all reported lower turnover: injection products amounted to RMB 786 million (down 23.6%), soft capsule products reached RMB 337 million (down 13.7%), granule products registered RMB 391 million (down 14.5%), TCM formula granule products totaled RMB 726 million (down 11.8%), and products in other forms stood at RMB 175 million (down 6.1%).</p>\n<p>In terms of product mix, injection products accounted for approximately 32.5% of the total turnover during the period, followed by TCM formula granule products at 30.1%. Soft capsule and granule products accounted for around 14.0% and 16.2%, respectively, while products in other forms represented the remainder, reflecting the group’s diversified product portfolio.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>China Shineway Pharmaceutical (2877) Announces RMB 2,415 Million Turnover for First Nine Months of 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChina Shineway Pharmaceutical (2877) Announces RMB 2,415 Million Turnover for First Nine Months of 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2025-11-07 12:23</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Shineway Pharmaceutical Group Limited (2877) recorded a turnover of RMB 2,415 million for the nine months ended 30 September 2025, reflecting a 16.3% decrease compared with the same period in 2024. Major product categories all reported lower turnover: injection products amounted to RMB 786 million (down 23.6%), soft capsule products reached RMB 337 million (down 13.7%), granule products registered RMB 391 million (down 14.5%), TCM formula granule products totaled RMB 726 million (down 11.8%), and products in other forms stood at RMB 175 million (down 6.1%).</p>\n<p>In terms of product mix, injection products accounted for approximately 32.5% of the total turnover during the period, followed by TCM formula granule products at 30.1%. Soft capsule and granule products accounted for around 14.0% and 16.2%, respectively, while products in other forms represented the remainder, reflecting the group’s diversified product portfolio.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02877","symbol_name":"神威药业","start_time":0,"source_url":"","article_id":"1142444254","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1142444254","pubTimestamp":1762489390,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Shineway Pharmaceutical Group Limited (2877) recorded a turnover of RMB 2,415 million for the nine months ended 30 September 2025, reflecting a 16.3% decrease compared with the same period in...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02877":"神威药业"},"translate_title":"神威药业(2877)公布2025年前9个月营业额24.15亿元","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02877":1},"content_text":"China Shineway Pharmaceutical Group Limited (2877) recorded a turnover of RMB 2,415 million for the nine months ended 30 September 2025, reflecting a 16.3% decrease compared with the same period in 2024. Major product categories all reported lower turnover: injection products amounted to RMB 786 million (down 23.6%), soft capsule products reached RMB 337 million (down 13.7%), granule products registered RMB 391 million (down 14.5%), TCM formula granule products totaled RMB 726 million (down 11.8%), and products in other forms stood at RMB 175 million (down 6.1%).\nIn terms of product mix, injection products accounted for approximately 32.5% of the total turnover during the period, followed by TCM formula granule products at 30.1%. Soft capsule and granule products accounted for around 14.0% and 16.2%, respectively, while products in other forms represented the remainder, reflecting the group’s diversified product portfolio.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}